Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept in Neovascular AMD (AURORA)
NCT01157715Phase 2Completed
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- May 2010
- Primary completion
- Jan 2012
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of conbercept in neovascular age-related macular degeneration (NVAMD) (2 cohorts), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd. Primary endpoints: Best Corrected Visual Acuity at 3 months and Incidence rate of adverse events at 3 months. Started May 2010; status: completed.
02
Drugs
conbercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01157715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01157715.